ライフサイエンスコーパス: primary effusion lymphoma

1 S, multicentric Castleman disease (MCD), and primary effusion lymphoma.

2 suppression, including Kaposi's sarcoma and primary effusion lymphoma.

3 open reading frames shown to be expressed in primary effusion lymphoma.

4 1 protein is expressed in Kaposi sarcoma and primary effusion lymphoma.

5 rus) has been linked to Kaposi's sarcoma and primary effusion lymphoma.

6 at induces Kaposi's sarcoma and AIDS-related primary effusion lymphoma.

7 activity and contribute to the phenotype of primary effusion lymphoma.

8 ric Castleman's disease, and AIDS-associated primary effusion lymphoma.

9 lex virus ICP27 genes, from an HHV8-infected primary effusion lymphoma.

10 ly etiological agent of Kaposi's sarcoma and primary effusion lymphoma.

11 iated with HHV8 include Kaposi's sarcoma and primary effusion lymphoma.

12 Kaposi's sarcoma and a rare B cell lymphoma, primary effusion lymphoma.

13 orders, multicentric Castleman's disease and primary effusion lymphoma.

14 rpesvirus (KSHV) causes Kaposi's sarcoma and primary effusion lymphoma.

15 ng AIDS-associated neoplasms, such as KS and primary-effusion lymphoma.

16 umors, multicentric Castleman's disease, and primary effusion lymphomas.

17 hogenesis of Kaposi's sarcoma, as well as in primary effusion lymphomas.

18 lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

19 to the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas.

20 (KS), multicentric Castleman's disease, and primary effusion lymphomas.

21 pathogenesis of Kaposi's sarcoma and B cell primary effusion lymphomas.

22 in the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas.

23 ; 4 of 11 AIDS-Burkitt lymphoma; 4 of 6 AIDS-primary effusion lymphoma; 1 of 4 AIDS-primary central n

24 with KS, multicentric Castleman disease, or primary effusion lymphoma and 8 HIV-uninfected men recei

25 ifest with Kaposi's sarcoma or less commonly primary effusion lymphoma and Castleman's disease; these

26 signaling in HHV-8 productive replication in primary effusion lymphoma and endothelial cells.

27 k6 complex exists in cell lines derived from primary effusion lymphoma and in Kaposi's sarcoma, this

28 present in all cases of Kaposi's sarcoma and primary effusion lymphoma and in some cases of multicent

29 t is implicated in B cell neoplasias such as primary effusion lymphoma and multicentric Castleman dis

30 ther lymphoproliferative diseases, including primary effusion lymphoma and multicentric Castleman's d

31 might also contribute to the pathogenesis of primary effusion lymphoma and multicentric Castleman's d

32 , and to hematologic malignancies, including primary effusion lymphoma and multicentric Castleman's d

33 cal factor of this malignancy, as well as of primary effusion lymphoma and multicentric Castleman's d

34 mplicated in Kaposi's sarcoma, as well as in primary effusion lymphoma and multicentric Castleman's d

35 a and with two lymphoproliferatve disorders, primary effusion lymphoma and multicentric Castleman's d

36 mmaherpesvirus that has been associated with primary effusion lymphoma and multicentric Castleman's d

37 ved in the pathogenesis of Kaposi's sarcoma, primary effusion lymphoma and some cases of multicentric

38 ith two B-cell lymphoproliferative diseases, primary effusion lymphoma and the plasmablastic form of

39 ays showed consistent expression of vIL-6 in primary effusion lymphomas and in a case of human immuno

40 Most primary effusion lymphomas and Kaposi's sarcoma tumor ce

41 h multicentric Castleman disease, and 1 with primary effusion lymphoma) and 1 asymptomatic PrEP user

42 B-cell lymphomas, such as Hodgkin lymphoma, primary effusion lymphoma, and a diffuse large B-cell ly

43 to the development of Kaposi's sarcoma (KS), primary effusion lymphoma, and a proportion of Castleman

44 endemic and AIDS-associated Kaposi sarcoma, primary effusion lymphoma, and Castleman disease.

45 Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease are t

46 aherpesvirus implicated in Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease, enco

47 erpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease.

48 ignancies: multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma.

49 ributing to development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman de

50 ent human malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman di

51 an malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

52 erpesvirus (KSHV) is tightly linked with KS, primary effusion lymphoma, and multicentric Castleman's

53 lignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's

54 an malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

55 ogic agent associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

56 is the etiologic agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

57 e different human cancers: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

58 s the etiological agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

59 ssociated with three human malignancies, KS, primary effusion lymphoma, and multicentric Castleman's

60 /HHV-8) has been linked to Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

61 ) has been associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

62 (KSHV) is associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

63 (HHV-8) is associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

64 d with the pathogenesis of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

65 stently identified in Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's

66 e etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman's

67 nked to the development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

68 ed with the development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

69 us is the etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and plasma cell-type multicen

70 is the infectious cause of Kaposi's sarcoma, primary effusion lymphoma, and plasmablastic multicentri

71 induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and some cases of Castleman d

72 s the etiological agent of Kaposi's sarcoma, primary effusion lymphoma, and some forms of multicentri

73 is etiologically linked to Kaposi's sarcoma, primary effusion lymphomas, and multicentric Castleman's

74 ted Kaposi's sarcoma (KS), body cavity-based primary effusion lymphomas, and multicentric Castleman's

75 tion using antagomirs in KSHV-infected human primary effusion lymphoma B cells resulted in derepressi

76 ion was explored by studying 2 KSHV-infected primary effusion lymphoma B-cell lines (BC-3 and BCBL-1)

77 ctor activity was expressed in KSHV-infected primary effusion lymphoma BCBL1 cells (TRExBCBL1-hNIC) i

78 rly, transient expression of siRNAs into the primary effusion lymphoma cell line BCBL-1 caused a subs

79 Infection of a primary effusion lymphoma cell line by vesicular stomati

80 In BC-1, a primary effusion lymphoma cell line that is dually infec

81 by diluting KSHV DNA from the KS-1 cells (a primary effusion lymphoma cell line which is estimated t

82 lytic KSHV replication in two KSHV-infected primary effusion lymphoma cell lines (BC-3 and BC-1) and

83 K3+1 expression in a subset of KSHV-infected primary effusion lymphoma cell lines as a consequence of

84 SHV mature microRNA expression in a panel of primary effusion lymphoma cell lines by real-time RT-PCR

85 ma-associated herpesvirus (KSHV)-transformed primary effusion lymphoma cell lines contain ~70 to 150

86 In vitro analysis of KSHV-infected primary effusion lymphoma cell lines in the presence of

87 as well as cocultivation with HHV-8-positive primary effusion lymphoma cell lines, activated the lacZ

88 rcoma-associated herpesvirus (KSHV)-infected primary effusion lymphoma cell lines, and its expression

89 As in all primary effusion lymphoma cell lines, there is a low lev

90 viral gene expression is similar to that of primary effusion lymphoma cell lines.

91 tetradecanoyl phorbol acetate-treated JSC-1 primary effusion lymphoma cell lysate, the levels of ass

92 VEC) infected through coculture with induced primary effusion lymphoma cells and telomerase-immortali

93 virus (KSHV) maintains a latent infection in primary effusion lymphoma cells but can be induced to en

94 in vitro and in vivo, and Kaposi sarcoma and primary effusion lymphoma cells demonstrate high levels

95 nvasiveness, as well as colony formation, by primary effusion lymphoma cells derived from human tumor

96 shown to be important for the maintenance of primary effusion lymphoma cells in culture and is chroni

97 Treatment of primary effusion lymphoma cells latently infected by Kap

98 esolution ChIP/deep sequencing from infected primary effusion lymphoma cells revealed that RBP-Jkappa

99 tic replication of KSHV in latently infected primary effusion lymphoma cells via beta-adrenergic acti

100 nd to LANA in transfected cells and in BCBL1 primary effusion lymphoma cells was found to be enriched

101 -I expression on EC and MHC-II expression on primary effusion lymphoma cells, but its effects on EC M

102 tion and survival of HHV-8 latently infected primary effusion lymphoma cells.

103 sodium butyrate and trichostatin A, in HH-B2 primary effusion lymphoma cells.

104 ey role in the survival and proliferation of primary effusion lymphoma cells.

105 ed a gene expression system in KSHV-infected primary effusion lymphoma cells.

106 he early lytic cycle of viral replication in primary effusion lymphoma cells.

107 istronic v-FLIP transcripts in KSHV-infected primary effusion lymphoma cells.

108 ISG induction and KSHV lytic reactivation in primary effusion lymphoma cells.

109 refore, we tested a BCL2 family inhibitor in primary effusion lymphoma cells.

110 dentified the teHsp90 interactome in KSHV(+) primary effusion lymphoma cells.

111 of KSHV lytic reactivation in KSHV-positive primary effusion lymphoma cells.

112 , and we administered them directly to human primary-effusion lymphoma cells infected with KSHV.

113 issues of patients with Kaposi's sarcoma and primary effusion lymphomas, contains a gene that encodes

114 Human primary effusion lymphoma-derived CD14+ cell-injected SC

115 containing the remaining 2 microRNAs from 5 primary effusion lymphoma-derived cell lines and from 17

116 NAs, we cloned small RNAs from KSHV-positive primary effusion lymphoma-derived cells and endothelial

117 in the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas, encodes a G protein-coupled

118 he etiological agent of Kaposi's sarcoma and primary effusion lymphoma, has developed a unique mechan

119 While attempting to establish primary effusion lymphoma in severe combined immunodefic

120 es Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients.

121 ymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and,

122 This novel antiviral approach to Primary Effusion lymphomas is targeted and may represent

123 KSHV causes primary effusion lymphomas, multicentric Castleman's dis

124 L; n = 61), plasmablastic lymphoma (n = 15), primary effusion lymphoma (n = 7), unclassifiable B-cell

125 Primary effusion lymphoma or body cavity-based lymphoma

126 bly range from Kaposi sarcoma (KS) to either primary effusion lymphoma or multicentric Castleman dise

127 context of reactivated lytic replication in primary effusion lymphoma (PEL) and endothelial cells an

128 family) were significantly down-regulated in primary effusion lymphoma (PEL) and in Kaposi sarcoma (K

129 of immunocompromised individuals, including primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS

130 B cell lymphoproliferative diseases, namely primary effusion lymphoma (PEL) and multicentric Castlem

131 ontribute to B-cell disorders, which include primary effusion lymphoma (PEL) and multicentric Castlem

132 ifferent human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castlem

133 tive disorders of these cells manifesting as primary effusion lymphoma (PEL) and multicentric Castlem

134 and two other lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castlem

135 Primary effusion lymphoma (PEL) and myeloma are lymphoid

136 is associated with two B cell malignancies, primary effusion lymphoma (PEL) and the plasmablastic va

137 h KS, in 6 (85.7%) of 7 HIV(+) patients with primary effusion lymphoma (PEL) and/or multicentric Cast

138 Primary effusion lymphoma (PEL) appears as an AIDS-defin

139 ells of classical Hodgkin lymphoma (cHL) and primary effusion lymphoma (PEL) are derived from germina

140 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) are two well-known infla

141 wn of miR-K1 in latently KSHV-infected human primary effusion lymphoma (PEL) B cells revealed a derep

142 NA-1) protein, and in KSHV latently infected primary effusion lymphoma (PEL) BCBL-1 and BC-3 cells.

143 is pathway.IMPORTANCE One hundred percent of primary effusion lymphoma (PEL) cases are associated wit

144 A primary effusion lymphoma (PEL) cell line, JSC-1, that y

145 In HH-B2, a newly established primary effusion lymphoma (PEL) cell line, KSHV ORF50 be

146 93 cells as well as the KSHV-infected BCBL-1 primary effusion lymphoma (PEL) cell line.

147 latency-associated nuclear antigen (LANA) in primary effusion lymphoma (PEL) cell lines and also incr

148 induction of lytic viral replication in both primary effusion lymphoma (PEL) cell lines and KS tumors

149 Primary effusion lymphoma (PEL) cell lines infected with

150 quences revealed that c-Myc in KSHV-positive primary effusion lymphoma (PEL) cell lines is wild type

151 d the expression of vGCR mRNA and protein in primary effusion lymphoma (PEL) cell lines, PEL and mult

152 cle can be induced in rare latently infected primary effusion lymphoma (PEL) cell lines, the ability

153 by chemicals that induce the lytic cycle in primary effusion lymphoma (PEL) cell lines.

154 Myc knockdown inhibited primary effusion lymphoma (PEL) cell proliferation throu

155 negatively impacting HHV-8 latently infected primary effusion lymphoma (PEL) cell viability and react

156 ibutes to the viability of latently infected primary effusion lymphoma (PEL) cells and to HHV-8 produ

157 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) cells are predominantly

158 Primary effusion lymphoma (PEL) cells are predominantly

159 e from all ~100 copies of the KSHV genome in primary effusion lymphoma (PEL) cells by coexpressing tw

160 nce-based knockdown of KAP1 in KSHV-infected primary effusion lymphoma (PEL) cells disrupted viral ep

161 Depletion of RPS6 from primary effusion lymphoma (PEL) cells dramatically decre

162 Examination of primary effusion lymphoma (PEL) cells found increased le

163 Primary effusion lymphoma (PEL) cells harbor Kaposi's sa

164 In primary effusion lymphoma (PEL) cells infected with late

165 e that vFLIP in BCBL-1 endogenously infected primary effusion lymphoma (PEL) cells mediates JNK/AP1 a

166 tance of iASPP to KSHV-infected-cell growth, primary effusion lymphoma (PEL) cells were treated with

167 epetitive region of LNA, detected antigen in primary effusion lymphoma (PEL) cells, and precipitated

168 , and 3 are also expressed during latency in primary effusion lymphoma (PEL) cells, and vIRF-1 and vI

169 rantly accumulated in KSHV latently infected primary effusion lymphoma (PEL) cells, as well as HEK293

170 ation of these proteins was also detected in primary effusion lymphoma (PEL) cells, as well as in a c

171 virus (KSHV) maintains a latent infection in primary effusion lymphoma (PEL) cells, but treatment wit

172 In primary effusion lymphoma (PEL) cells, vIL-6 is expresse

173 i's sarcoma-associated herpesvirus (KSHV) in primary effusion lymphoma (PEL) cells.

174 ces in tetradecanoyl phorbol acetate-induced primary effusion lymphoma (PEL) cells.

175 angiogenesis and the survival and growth of primary effusion lymphoma (PEL) cells.

176 ctivation, and proliferation of BCR-negative primary effusion lymphoma (PEL) cells.

177 KSHV and Epstein-Barr virus-coinfected JSC1 primary effusion lymphoma (PEL) cells.

178 s of the viral cytokine in latently infected primary effusion lymphoma (PEL) cells.

179 etected in KS lesions and in KSHV-associated primary effusion lymphoma (PEL) cells.

180 Primary effusion lymphoma (PEL) constitutes a subset of

181 ts low-level expression in latently infected primary effusion lymphoma (PEL) cultures, in the absence

182 this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are r

183 s (KSHV) is necessary but not sufficient for primary effusion lymphoma (PEL) development.

184 Primary effusion lymphoma (PEL) has a very poor prognosi

185 man herpesvirus 8) has been linked to KS and primary effusion lymphoma (PEL) in immunocompromised ind

186 rus) has been linked to Kaposi's sarcoma and primary effusion lymphoma (PEL) in immunocompromised ind

187 e (RNAi) to inhibit the growth of a model of primary effusion lymphoma (PEL) in vitro and in vivo.

188 Primary effusion lymphoma (PEL) is a B-cell lymphoma in

189 Primary effusion lymphoma (PEL) is a diffuse-large B-cel

190 Primary effusion lymphoma (PEL) is a distinct clinicopat

191 Primary effusion lymphoma (PEL) is a distinct type of B-

192 Primary effusion lymphoma (PEL) is a distinct type of ly

193 Primary effusion lymphoma (PEL) is a highly aggressive B

194 Primary effusion lymphoma (PEL) is a largely incurable m

195 Primary effusion lymphoma (PEL) is a lymphogenic disorde

196 Primary effusion lymphoma (PEL) is a non-Hodgkin's B-cel

197 Primary effusion lymphoma (PEL) is a rare B-cell lymphom

198 Primary effusion lymphoma (PEL) is a rare B-cell neoplas

199 Primary effusion lymphoma (PEL) is a rare form of aggres

200 Primary effusion lymphoma (PEL) is a rare subtype of non

201 Primary effusion lymphoma (PEL) is a subtype of non-Hodg

202 human B-cell non-Hodgkin lymphomas (B-NHL), primary effusion lymphoma (PEL) is a unique subset that

203 Primary effusion lymphoma (PEL) is an aggressive B-cell

204 Primary effusion lymphoma (PEL) is an aggressive form of

205 Primary effusion lymphoma (PEL) is an aggressive HIV-ass

206 Primary effusion lymphoma (PEL) is an aggressive maligna

207 Primary effusion lymphoma (PEL) is an aggressive subtype

208 Primary effusion lymphoma (PEL) is an aggressive type of

209 Primary effusion lymphoma (PEL) is an AIDS-defining canc

210 AIDS-related primary effusion lymphoma (PEL) is an HIV-associated mal

211 The role of p53 in primary effusion lymphoma (PEL) is complicated.

212 ations, the vIRF3-expressing KSHV-associated primary effusion lymphoma (PEL) lines are generally resi

213 ads in molecular pathogenesis, AIDS-defining primary effusion lymphoma (PEL) remains a fatal malignan

214 -related human herpesvirus type 8-associated primary effusion lymphoma (PEL) responds poorly to chemo

215 cell lines and 6 Kaposi's sarcoma (KS) and 4 primary effusion lymphoma (PEL) tumor samples from the U

216 vital for the survival and proliferation of primary effusion lymphoma (PEL), an aggressive malignanc

217 KSHV is linked to primary effusion lymphoma (PEL), and 90% of PELs also co

218 (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a form of Castleman

219 the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multice

220 s the etiological agent of Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

221 V) is associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

222 etiologically linked to Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

223 herpesvirus 8, is an etiologic agent of KS, primary effusion lymphoma (PEL), and multicentric Castle

224 pesvirus is linked to Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

225 and -unrelated cases of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

226 ed herpesvirus (KSHV) is associated with KS, primary effusion lymphoma (PEL), and multicentric Castle

227 ed in the etiology of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

228 vities to HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

229 the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

230 cally associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

231 teins, in HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

232 ibutor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

233 to the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

234 oliferative diseases: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

235 fection is associated with Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

236 veral neoplastic diseases: Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

237 ing region of KSHV from Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

238 uding diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL), and multiple myeloma (M

239 Certain lymphomas in AIDS patients, such as primary effusion lymphoma (PEL), are closely associated

240 ed tumors, such as Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), are of endothelial and

241 ly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), defective KSHV has not

242 V), a virus linked to malignancies including primary effusion lymphoma (PEL), encodes 12 miRNA genes,

243 th 3 distinct lymphoproliferative disorders: primary effusion lymphoma (PEL), multicentric Castleman

244 herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL), multicentric Castleman'

245 regulated and important for cell survival in primary effusion lymphoma (PEL), which is a viral lympho

246 ammatory protein 1A (vMIP-1A) and vMIP-1B in primary effusion lymphoma (PEL)-derived cell lines and e

247 etiologic agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

248 multicentric Castleman's disease (MCD), and primary effusion lymphoma (PEL).

249 rs, multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL).

250 herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).

251 c agent associated with Kaposi's sarcoma and primary effusion lymphoma (PEL).

252 cells in patients with Kaposi's sarcoma and primary effusion lymphoma (PEL).

253 tiologic agent for Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

254 causative agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

255 tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

256 responsible for Kaposi's sarcoma as well as primary effusion lymphoma (PEL).

257 that causes Kaposi sarcoma and AIDS-related primary effusion lymphoma (PEL).

258 lso linked to the rare B-cell tumor known as primary effusion lymphoma (PEL).

259 ith multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL).

260 ls and in HHV-8-associated tumors, including primary effusion lymphoma (PEL).

261 cts human lymphocytes and is associated with primary effusion lymphoma (PEL).

262 n's disease (CD), Kaposi's sarcoma (KS), and primary effusion lymphoma (PEL).

263 he etiological agent of Kaposi's sarcoma and primary effusion lymphoma (PEL).

264 nancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

265 nancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

266 ociated with several malignancies, including primary effusion lymphoma (PEL).

267 nancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

268 ly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

269 multicentric Castleman's disease (MCD), and primary effusion lymphoma (PEL).

270 malignancies, including Kaposi's sarcoma and primary effusion lymphoma (PEL).

271 ts with AIDS-related Kaposi sarcoma (KS) and primary effusion lymphoma (PEL).

272 cy Kaposi sarcoma, or the B-cell malignancy, primary effusion lymphoma (PEL).

273 on and suppression of NF-kappaB signaling in primary effusion lymphoma (PEL).

274 functions of ANG in KSHV-positive (KSHV(+)) primary effusion lymphoma (PEL/BCBL) cells.

275 th two additional AIDS-related malignancies: primary effusion lymphomas (PEL) and multicentric Castle

276 Primary effusion lymphomas (PEL) are associated with hum

277 The majority of AIDS-associated primary effusion lymphomas (PEL) are latently infected w

278 human immunodeficiency virus (HIV)- related primary effusion lymphomas (PEL), a sensitive enzyme-lin

279 sociated herpesvirus (KSHV) is linked to KS, primary effusion lymphomas (PEL), and a subset of multic

280 lines, a type III latency line, three EBV(+) primary effusion lymphomas (PEL), and three AIDS-related

281 ) are found together in approximately 80% of primary effusion lymphomas (PEL), but their contribution

282 ciated with Kaposi's sarcoma (KS) as well as primary effusion lymphomas (PEL).

283 n Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Lymphomas (PEL).

284 irus (KSHV or HHV8) sequences are present in primary effusion lymphomas (PEL).

285 known to be an etiologic force behind KS and primary-effusion lymphoma (PEL).

286 Primary effusion lymphomas (PELs) are causally associate

287 Primary effusion lymphomas (PELs) are specifically assoc

288 Primary effusion lymphomas (PELs) associated with infect

289 KSHV-associated primary effusion lymphomas (PELs) secrete high levels of

290 d mature miRNA levels for the largest set of primary effusion lymphomas (PELs) to date.

291 of Kaposi's sarcoma (KS), body-cavity-based, primary effusion lymphomas (PELs), and a subset of Castl

292 rpesvirus (KSHV) latently infects KS tumors, primary effusion lymphomas (PELs), and PEL cell lines.

293 n herpesvirus 8) latently infects KS tumors, primary effusion lymphomas (PELs), and PEL cell lines.

294 Primary effusion lymphomas (PELs), which are rare lympho

295 with numerous human malignancies, including primary effusion lymphomas (PELs).

296 , as well as a rare form of B cell lymphoma (primary effusion lymphoma) primarily observed in HIV-inf

297 present in all cases of Kaposi's sarcoma and primary effusion lymphoma, provide opportunities for sel

298 n Kaposi sarcoma herpesvirus (KSHV)-infected primary effusion lymphoma through down-regulation of the

299 gher in latently infected cells derived from primary effusion lymphomas; thus, it appears that HHV-8

300 ly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma, with viral genomes present in